Lilly's new drug for Alzheimer's disease, Kisunla, has been approved by the US FDA. On July 2nd, Lilly announced that the US Food and Drug Administration (FDA) has approved Kisunla for the treatment of adult patients with early symptoms of Alzheimer's disease. The cost for the first year is $32000. If the plaques in the brain drop to the lowest level, doctors can choose to stop taking the medication. The company claims that in trials about a year later, many people stopped treatment. After the news of Kisunlia's approval was announced, Lilly's competitor Bojian fell by 2.8% during trading.